Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supinoxin in advanced solid tumors and TNBC
NCT02003092Phase 2Terminated
- Sponsor
- Rexahn Pharmaceuticals
- Start
- Aug 2013
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of supinoxin in solid tumor, triple-negative breast cancer (TNBC), sponsored by Rexahn Pharmaceuticals. Started Aug 2013; status: terminated.
02
Drugs
supinoxin
03
Conditions
solid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02003092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02003092.